Kevin M. Brady Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 day, 17 hours ago
Kevin M. Brady has an estimated net worth of at least $12.5 million*, as of March 11, 2026. They own 5,830 shares of MEDP stock. They have sold 25,250 shares of MEDP stock since 2021, for an estimated $9.7 million.
Kevin M. Brady $MEDP SEC Form 4 Insider Trading
Kevin M. Brady has filed a total of 6 insider trades in $MEDP since 2021. Their most recent trade was a sale of 3,000 shares, made on Nov 21, 2025. Their largest trade was a sale of 12,000 shares, made on Jul 24, 2025. We estimate that they now own 5,830 shares of $MEDP, worth an estimated $2.7 million.
Insider Trading at $MEDP
There have been a total of 306 insider trades reported at $MEDP since 2021, with 2.0 million shares purchased and 5.7 million shares sold. The most active insider traders in $MEDP stock have been August J. Troendle, August J. Troendle, and Susan E Burwig. The most recent trade was a sale of 668 shares reported by August J. Troendle (CEO), made on Dec 03, 2025.
History of Insider Stock Trades by Kevin M. Brady
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
MEDP
|
Sale | 3,000 | Nov 21, 2025 | Nov. 25, 2025, 5:40 p.m. |
|
MEDP
|
Sale | 12,000 | Jul 24, 2025 | July 28, 2025, 5:08 p.m. |
|
MEDP
|
Sale | 7,000 | Jul 31, 2023 | Aug. 2, 2023, 4:15 p.m. |
|
MEDP
|
Sale | 1,656 | Nov 15, 2022 | Nov. 17, 2022, 5:21 p.m. |
|
MEDP
|
Sale | 344 | Nov 16, 2022 | Nov. 17, 2022, 5:21 p.m. |
|
MEDP
|
Sale | 1,250 | Nov 02, 2021 | Nov. 3, 2021, 8 p.m. |
$MEDP Executives and Stock Owners with Insider Trades
-
August J. Troendle, CEO
-
August J. Troendle, President & CEO
-
Susan E Burwig, Exec. VP, Operations
-
Jesse J Geiger, President
-
Stephen P Ewald, General Counsel & Corp. Secy.
-
Kevin M. Brady, CFO & Treasurer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.